Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an announcement.
Tasly Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a slight increase in revenue and net profit compared to the same period in 2024. Despite a decrease in cash and cash equivalents, the company’s total assets and owner’s equity remained stable, indicating a steady financial position. Stakeholders are advised to exercise caution as the financials have not been audited and may be subject to adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of medical and pharmaceutical products. The company holds a significant equity interest in Tasly Pharmaceuticals, a company listed on the Shanghai Stock Exchange, and is involved in its management through its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.51B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue